SG Americas Securities LLC Increases Holdings in Certara, Inc. (NASDAQ:CERT)

SG Americas Securities LLC grew its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 350.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 69,727 shares of the company's stock after purchasing an additional 54,235 shares during the quarter. SG Americas Securities LLC's holdings in Certara were worth $690,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its holdings in Certara by 3.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock worth $253,000 after purchasing an additional 823 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the period. Bank of Montreal Can increased its position in shares of Certara by 9.1% during the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock worth $212,000 after buying an additional 1,670 shares during the period. Versant Capital Management Inc raised its stake in Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after buying an additional 1,866 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC lifted its holdings in Certara by 20.5% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company's stock valued at $138,000 after buying an additional 2,202 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CERT has been the subject of a number of recent analyst reports. TD Cowen initiated coverage on Certara in a research report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective for the company. KeyCorp raised their target price on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. William Blair reissued a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. Finally, Stephens reiterated an "overweight" rating and issued a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Certara currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Stock Up 2.2%

CERT traded up $0.23 during trading on Tuesday, hitting $10.69. 1,488,252 shares of the company's stock were exchanged, compared to its average volume of 1,415,524. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $16.93. The stock has a market cap of $1.73 billion, a P/E ratio of -534.50 and a beta of 1.44. The business's 50 day moving average is $12.17 and its two-hundred day moving average is $11.86. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The firm's revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. As a group, equities analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.